TuisSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Vorige sluiting
$1,97
Jaarwisseling
$1,97 - $2,95
Markkapitalisasie
63,04 mjd HKD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
HKG
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 147,46 mjd | -5,13% |
Bedryfskoste | 6,38 mjd | -2,07% |
Netto inkomste | 2,28 mjd | -9,16% |
Netto winsgrens | 1,55 | -4,32% |
Wins per aandeel | — | — |
EBITDA | 5,57 mjd | -12,42% |
Effektiewe belastingkoers | 21,74% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 43,33 mjd | 26,05% |
Totale bates | 429,58 mjd | 2,85% |
Totale aanspreeklikheid | 307,15 mjd | 0,84% |
Totale ekwiteit | 122,43 mjd | — |
Uitstaande aandele | 3,12 mjd | — |
Prys om te bespreek | 0,08 | — |
Opbrengs op bates | 2,96% | — |
Opbrengs op kapitaal | 5,84% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,28 mjd | -9,16% |
Kontant van bedrywe | 6,49 mjd | 346,39% |
Kontant van beleggings | -1,29 mjd | -269,35% |
Kontant van finansiering | -602,70 m | -425,16% |
Netto kontantverandering | 4,59 mjd | 374,61% |
Beskikbare kontantvloei | -22,56 mjd | 29,73% |
Meer oor
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Gestig
2003
Webwerf
Werknemers
113 635
